JP2025504984A5 - - Google Patents

Info

Publication number
JP2025504984A5
JP2025504984A5 JP2024545781A JP2024545781A JP2025504984A5 JP 2025504984 A5 JP2025504984 A5 JP 2025504984A5 JP 2024545781 A JP2024545781 A JP 2024545781A JP 2024545781 A JP2024545781 A JP 2024545781A JP 2025504984 A5 JP2025504984 A5 JP 2025504984A5
Authority
JP
Japan
Prior art keywords
day
composition according
ibudilast
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504984A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011931 external-priority patent/WO2023150093A1/en
Publication of JP2025504984A publication Critical patent/JP2025504984A/ja
Publication of JP2025504984A5 publication Critical patent/JP2025504984A5/ja
Pending legal-status Critical Current

Links

JP2024545781A 2022-02-01 2023-01-31 Covid後症状の治療における使用のためのイブジラスト Pending JP2025504984A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305483P 2022-02-01 2022-02-01
US63/305,483 2022-02-01
PCT/US2023/011931 WO2023150093A1 (en) 2022-02-01 2023-01-31 Ibudilast for use in the treatment of post-covid conditions

Publications (2)

Publication Number Publication Date
JP2025504984A JP2025504984A (ja) 2025-02-19
JP2025504984A5 true JP2025504984A5 (cg-RX-API-DMAC7.html) 2026-02-03

Family

ID=85382992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545781A Pending JP2025504984A (ja) 2022-02-01 2023-01-31 Covid後症状の治療における使用のためのイブジラスト

Country Status (6)

Country Link
US (1) US12171752B2 (cg-RX-API-DMAC7.html)
EP (1) EP4472631A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504984A (cg-RX-API-DMAC7.html)
CN (1) CN118973574A (cg-RX-API-DMAC7.html)
CA (1) CA3251194A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023150093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562198A (en) 1998-08-10 2000-03-06 Kyorin Pharmaceutical Co. Ltd. Remedies for multiple sclerosis
WO2006063048A2 (en) * 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
EP2026804A1 (en) 2006-05-31 2009-02-25 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2693697C (en) 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CN115335049A (zh) 2020-04-06 2022-11-11 美迪诺亚公司 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法
GB202005890D0 (en) * 2020-04-22 2020-06-03 Aivivo Ltd New uses
WO2022181219A1 (ja) 2021-02-24 2022-09-01 国立大学法人九州大学 新興ウイルス感染症治療薬

Similar Documents

Publication Publication Date Title
Jermain et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study
JPH0789851A (ja) 置換フェネチルアミン類を用いた医薬組成物
JP2025511081A5 (cg-RX-API-DMAC7.html)
JP7758320B2 (ja) 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法
JP2026512418A (ja) モノアミン抗うつ薬および短時間作用型サイケデリック剤を含む組合せ
Eser et al. Agomelatine: the evidence for its place in the treatment of depression
Chang et al. Antidepressant drugs: mechanisms of action and side effects
Elmer et al. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy
US20230145635A1 (en) Treatment of menstrual cycle-induced symptoms
Junkes et al. MAO inhibitors for treatment-resistant depression: Bringing an updated perspective on pioneering drugs
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
Michaels et al. Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors
Uddin et al. Amphetamines: Potent recreational drug of abuse
Kelmendi et al. Clinical evidence for the use of methylone in the treatment of PTSD: A case series with long-term follow-up
JP2024531799A5 (cg-RX-API-DMAC7.html)
TWI752282B (zh) 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途
Srinivasan et al. Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
JP2023552833A5 (ja) 薬物使用障害を治療するための薬剤、薬物使用障害患者による薬物使用の低減における治療のための薬剤、薬物使用障害患者による薬物使用の再発を予防するための治療のための薬剤、薬物使用障害患者による薬物禁断を促進する治療のための薬剤及び薬物使用障害に関連するうつ病又は不安の症状を治療するための薬剤
Habib et al. Role of Beta-Blockers as an Effective Cardio protective Agents, an insight in to Tackling with Cardiovascular Diseases (CVDs) and Hypertension
Vasile et al. P. 2. c. 002 Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus
Vilayet et al. Bupropion toxicity causing refractory cardiogenic shock successfully treated with mechanical circulatory support: a case report
Kowshihan et al. Effectiveness of Paroxetine in Controlling Anxiety during Tooth Preparation—A Prospective Trial
TW202024040A (zh) 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途
Il’ina Experience of the use of velaxin (venlafaxine) in anxious depression
Behere et al. Antidepressants